» Articles » PMID: 25787729

Multifunctional Nanoparticles for Use in Theranostic Applications

Overview
Publisher Springer
Specialty Pharmacology
Date 2015 Mar 20
PMID 25787729
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Theranostics is a promising field that combines therapeutics and diagnostics into single multifunctional formulations. This field is driven by advancements in nanoparticle systems capable of providing the necessary functionalities. By utilizing these powerful nanomedicines, the concept of personalized medicine can be realized by tailoring treatment strategies to the individual. This review gives a brief overview of the components of a theranostic system and the challenges that designing truly multifunctional nanoparticles present. Considerations when choosing a class of nanoparticle include the size, shape, charge, and surface chemistry, while classes of nanoparticles discussed are polymers, liposomes, dendrimers, and polymeric micelles. Targeting to disease states can be achieved either through passive or active targeting which uses specific ligands to target receptors that are overexpressed in tumors and common targeting elements are presented. To image the interactions with disease states, contrast agents are included in the nanoparticle formulation. Imaging options include optical imaging techniques, computed tomography, nuclear based, and magnetic resonance imaging. The interplay between all of these components needs to be carefully considered when designing a theranostic system.

Citing Articles

Theoretical and Experimental Analyses of the Interfacial Mechanism of Dendrimer-Doxorubicin Complexes Formation.

Jachimska B, Goncerz M, Wolski P, Meldrum C, Lustyk L, Panczyk T Mol Pharm. 2024; 21(11):5892-5904.

PMID: 39436101 PMC: 11539063. DOI: 10.1021/acs.molpharmaceut.4c00941.


Exploring the Potential of Nanogels: From Drug Carriers to Radiopharmaceutical Agents.

Kubeil M, Suzuki Y, Casulli M, Kamal R, Hashimoto T, Bachmann M Adv Healthc Mater. 2023; 13(1):e2301404.

PMID: 37717209 PMC: 11468994. DOI: 10.1002/adhm.202301404.


Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.

Li J, Wang Q, Han Y, Jiang L, Lu S, Wang B J Hematol Oncol. 2023; 16(1):65.

PMID: 37353849 PMC: 10290401. DOI: 10.1186/s13045-023-01460-2.


Naphth[1,2-]imidazoles Bioactive from β-Lapachone: Fluorescent Probes and Cytotoxic Agents to Cancer Cells.

Santos V, Gonsalves A, Guimaraes D, Simplicio S, de Oliveira H, Ramos L Molecules. 2023; 28(7).

PMID: 37049771 PMC: 10096064. DOI: 10.3390/molecules28073008.


Biogenic Selenium Nanoparticles in Biomedical Sciences: Properties, Current Trends, Novel Opportunities and Emerging Challenges in Theranostic Nanomedicine.

Zambonino M, Quizhpe E, Mouheb L, Rahman A, Agathos S, Dahoumane S Nanomaterials (Basel). 2023; 13(3).

PMID: 36770385 PMC: 9921003. DOI: 10.3390/nano13030424.


References
1.
Wang R, Niu Y, Wu H, Amin M, Cai J . Development of NGR peptide-based agents for tumor imaging. Am J Nucl Med Mol Imaging. 2012; 1(1):36-46. PMC: 3477716. View

2.
Sudimack J, Lee R . Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000; 41(2):147-62. DOI: 10.1016/s0169-409x(99)00062-9. View

3.
Cho K, Wang X, Nie S, Chen Z, Shin D . Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008; 14(5):1310-6. DOI: 10.1158/1078-0432.CCR-07-1441. View

4.
Allen T, Cullis P . Drug delivery systems: entering the mainstream. Science. 2004; 303(5665):1818-22. DOI: 10.1126/science.1095833. View

5.
Hersel U, Dahmen C, Kessler H . RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials. 2003; 24(24):4385-415. DOI: 10.1016/s0142-9612(03)00343-0. View